PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27470969.
- Also identified by DOI 10.1158/1078-0432.CCR-16-1401 and PMC identifier 5653962.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immunotherapeutics for advanced smoking-associated non-small cell lung cancer. Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. Clin Cancer Res; 22(18); 4539-41. ©2016 AACRSee related article by Gainor et al., p. 4585.
Medical subject headings
- Antineoplastic Agents
- ErbB Receptors
- Lung Neoplasms
- Programmed Cell Death 1 Receptor
- Receptor Protein-Tyrosine Kinases